Bromo-DragonFLY is an extremely potent psychedelic-hallucinogenic drug related to the phenethylamine family. Its hallucinogenic potency is slightly less than that of LSD with a normal dose in the region of 200 mcg to 800 mcg, but it lasts much longer than LSD, capable of up to 36 hours of intoxication. The hallucinogenic effects are believed to be mediated by its antagonist activity at the 5-HT2A serotonin receptor. A similar strong affinity for peripheral serotonin receptors is believed to induce prolonged and severe narrowing of the body’s blood vessels, which has resulted in tissue necrosis (dead tissue) following Bromo-DragonFLY use.
Bromo-DragonFLY was first synthesized in 1998 by Matthew Parker in the laboratory of David E. Nichols. Bromo-DragonFLY was named after its superficial structural resemblance to a dragonfly. Its chemical name is bromo-benzodifuranyl-isopropylamine. The drug is sold either in the form of powder or paper blotters, similar to the distribution method of LSD, which has led to confusion and reports of mistakenly consuming Bromo-DragonFLY.
Bromo-dragonFLY is explicitly illegal in some European countries like Finland, Sweden, Norway and Denmark. On the other hand, it may be considered a controlled substance under U.S. and Australian drug laws.
The effects of Bromo-DragonFLY are not well understood in humans. Reactions and experiences may vary dramatically from person to person:
Tests for Bromo-DragonFLY are now available and include a fully validated quantitative procedure with a detection limit of 1.0 ng/mL. The method utilizes a state of the art high-performance liquid chromatography-tandem mass spectrometry technique. The urine test for Bromo-DragonFLY follows a screen and conditional confirmation procedure, meaning samples identified as potentially positive in initial drug testing will be confirmed using a secondary procedure.
